MX2021004280A - Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. - Google Patents

Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.

Info

Publication number
MX2021004280A
MX2021004280A MX2021004280A MX2021004280A MX2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A MX 2021004280 A MX2021004280 A MX 2021004280A
Authority
MX
Mexico
Prior art keywords
pyrazole derivatives
antagonist compounds
sup
compounds
ameliorating
Prior art date
Application number
MX2021004280A
Other languages
English (en)
Inventor
Giles Albert Brown
Miles Stuart Congreve
Mark Pickworth
Charlotte Fieldhouse
Barry John Teobald
Nigel Alan Swain
Giovanni Bottegoni
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of MX2021004280A publication Critical patent/MX2021004280A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Las invenciones de este documento se refieren a nuevos compuestos de la fórmula (1): (ver Fórmulas) y sales de los mismos, en donde A; X; n; R1 y R2 se definen en este documento y su uso para tratar, prevenir, mejorar, controlar o reducir el riesgo de trastornos asociados con los receptores H4.
MX2021004280A 2018-10-19 2019-10-21 Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. MX2021004280A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1817047.2A GB201817047D0 (en) 2018-10-19 2018-10-19 H4 antagonist compounds
PCT/GB2019/052997 WO2020079457A1 (en) 2018-10-19 2019-10-21 Pyrazole derivatives as h4 antagonist compounds

Publications (1)

Publication Number Publication Date
MX2021004280A true MX2021004280A (es) 2021-05-31

Family

ID=64453795

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004280A MX2021004280A (es) 2018-10-19 2019-10-21 Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.

Country Status (12)

Country Link
US (1) US20210300906A1 (es)
EP (1) EP3867248A1 (es)
JP (1) JP2022507013A (es)
KR (1) KR20210079318A (es)
CN (1) CN113272297B (es)
AU (1) AU2019360428B2 (es)
BR (1) BR112021007372A2 (es)
CA (1) CA3116628A1 (es)
GB (1) GB201817047D0 (es)
MX (1) MX2021004280A (es)
SG (1) SG11202103133QA (es)
WO (1) WO2020079457A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005858D0 (en) * 2020-04-22 2020-06-03 Heptares Therapeutics Ltd H4 Antagonist compounds
WO2022203399A1 (ko) * 2021-03-26 2022-09-29 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
WO2023068200A1 (ja) * 2021-10-19 2023-04-27 ユニマテック株式会社 含フッ素ピラゾール化合物およびその製造方法
KR102621694B1 (ko) * 2022-09-15 2024-01-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103551A1 (en) * 1998-07-24 2001-05-30 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives and salts thereof
WO2005054239A1 (en) * 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
NL2000323C2 (nl) * 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物

Also Published As

Publication number Publication date
JP2022507013A (ja) 2022-01-18
AU2019360428A1 (en) 2021-04-29
SG11202103133QA (en) 2021-05-28
US20210300906A1 (en) 2021-09-30
GB201817047D0 (en) 2018-12-05
WO2020079457A1 (en) 2020-04-23
CN113272297A (zh) 2021-08-17
KR20210079318A (ko) 2021-06-29
BR112021007372A2 (pt) 2021-07-20
EP3867248A1 (en) 2021-08-25
CA3116628A1 (en) 2020-04-23
AU2019360428B2 (en) 2024-05-09
CN113272297B (zh) 2024-03-19

Similar Documents

Publication Publication Date Title
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
MX371167B (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ733899A (en) [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX2022011333A (es) Compuestos moduladores de gpr52.
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
MX2020012978A (es) Sales de sepiapterina farmacéuticamente aceptables.
EP4001273A3 (en) Aminopyrimidines as alk inhibitors
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
SG11201907945YA (en) Azetidine derivative
AU2024202343A1 (en) Combination comprising decanoic acid for the treatment of epilepsy
PH12019501566A1 (en) Amide compounds and use thereof
MX2020010086A (es) Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
PH12021551157A1 (en) Ketamine pamoate and use thereof
WO2020074927A3 (en) Glp-1 receptor antagonists
MX2023006972A (es) Compuestos antagonistas de h4.
MY189372A (en) Indole derivatives
CA3156131A1 (en) PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS